Suppression of presbyopia progression with pirenoxine eye drops: experiments on rats and non-blinded, randomized clinical trial of efficacy Various methods can correct presbyopia, but all require devices or surgeries. Recently, supplements or warming devices to relieve presbyopic symptoms have been developed, but no eye drops have been developed. We screened certain compounds possibly related to lens degeneration and identified pirenoxine, which has been used for cataracts, as a possible new pharmacologic treatment for presbyopia. We first researched the anti-presbyopic activity of pirenoxine in rats. The lens elasticity significantly (p = 0.028) increased with exposure to tobacco smoke for 12 days, and pirenoxine eye drops significantly (p < 0.001) suppressed lens hardening, which causes
Noninvasive monitoring of Pirenoxine Sodium concentration in aqueous humor based on dual-wavelength iris imaging technique We present a noninvasive method of detecting substance concentration in the aqueous humor based on dual-wavelength iris imaging technology. Two light sources, one centered within (392 nm) and the other centered outside (850 nm) of an absorption band of Pirenoxine Sodium , a common type of drugs in eye disease treatment, were used for dual-wavelength iris imaging measurement. After passing through the aqueous humor twice, the back-scattering light was detected by a charge-coupled device (CCD). The detected images were then used to calculate the concentration of Pirenoxine Sodium. In eye model experiment, a resolution of 0.6525 ppm was achieved. Meanwhile, at least 4 ppm